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A wide range of adipokines identified over the past years has allowed considering the
white adipose tissue as a secretory organ closely integrated into overall physiological
and metabolic control. Apelin, a ubiquitously expressed peptide was known to exert
different physiological effects mainly on the cardiovascular system and the regulation of
fluid homeostasis prior to its characterization as an adipokine. This has broadened its
range of action and apelin now appears clearly as a new player in energy metabolism
in addition to leptin and adiponectin. Apelin has been shown to act on glucose and
lipid metabolism but also to modulate insulin secretion. Moreover, different studies in
both animals and humans have shown that plasma apelin concentrations are usually
increased during obesity and type 2 diabetes. This mini-review will focus on the various
systemic apelin effects on energy metabolism by addressing its mechanisms of action.
The advances concerning the role of apelin in metabolic diseases in relation with the
recent reports on apelin concentrations in obese and/or diabetic subjects will also be
discussed.
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Introduction
Nutrient metabolism and energy homeostasis are tightly regulated by endocrine, paracrine, and
autocrine factors. Moreover, skeletal muscle, liver, adipose tissue and pancreatic β-cells play a major
role in the maintenance of energy balance. A rapid modification of energy balance leads to obesity
that in turn is a crucial cause of insulin resistance. Several mechanisms linking obesity to insulin
resistance have been proposed. Among them, adipocyte-secreted factors or adipokines have been
shown to play an important role. Alteration of their production (excess or deficit) could directly
promote or delay the onset of insulin resistance. The role of leptin and adiponectin has been
extensively studied (for review see Lafontan and Viguerie, 2006; Tishinsky et al., 2012; Farooqi
and O’Rahilly, 2014). In 1998 Tatemoto et al identified apelin as the ligand of the APJ receptor,
a G protein coupled receptor (Tatemoto et al., 1998). Apelin gene encodes for a 77 amino acid
preproprotein and the apelin propeptide contains several doublets of basic amino acids impli-
cating potential proteolytic cleavage sites for endopeptidases which give rise to several bioactive
carboxy-terminal fragments including apelin-36, apelin-17, and apelin-13 but also the pyrogluta-
mate apelin-13 which is protected from exopeptidase degradation (Masri et al., 2005). The group
of Tatemoto has described the presence of apelin in rat adipose tissue (Wei et al., 2005) but the
actual secretion from human and murine adipocytes was reported by Boucher et al. demonstrat-
ing that apelin was a new adipokine (Boucher et al., 2005). Apelin and its receptor APJ are widely
expressed in several tissues (stomach, heart, lung, skeletal muscle, etc.) and in different regions of
the brain, including the hypothalamus (O’Carroll et al., 2013). The apelin/APJ system is involved
in a wide range of functions. Neither the effects of apelin on the regulation of cardiac and vascular
functions, fluid homeostasis and angiogenesis, (Chapman et al., 2014) nor its central actions
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on energy metabolism (Knauf et al., 2013) are presented in this
article since these aspects were recently reviewed. This mini-
review will discuss the recent advances concerning the role of
apelin on energy metabolism particularly in pathophysiological
situations (obesity, type 2 diabetes) and will try to establish a link
between plasma apelin concentrations and metabolic diseases in
humans.
Apelin and Glucose Metabolism
One of the first apelin effects observed on glucose metabolism,
apart from that on insulin secretion (Sorhede Winzell et al.,
2005), is its glucose-lowering effect both in fasted conditions
and during a glucose tolerance test (Dray et al., 2008) in stan-
dard mice. This decreased glycemia has been shown to be mainly
due to increased glucose uptake in target tissues such as skeletal
muscle and adipose tissue (Dray et al., 2008). Since the muscles
represent the main entry of glucose, apelin effect was studied in
isolated soleus muscle. Apelin stimulated glucose transport and
its effect was additive to that of insulin (Dray et al., 2008). The
signaling pathway was depicted and it was shown that apelin
stimulated the phosphorylation of the AMP-activated protein
kinase (AMPK) but also the endothelial NO synthase (eNOS)
(Dray et al., 2008). The importance of both enzymes has been
demonstrated by the use of eNOS−/− mice and DN-AMPKmice
(muscle-specific inactive AMPK) respectively. Later on, the study
of Yue et al. also reported that apelin was able to stimulate glu-
cose transport in vitro in C2C12 muscle cells through a pathway
involving AMPK but not eNOS (Yue et al., 2010). This discrep-
ancy could be due to the fact that NOS inhibitors were used in
the study of Yue et al. and that these inhibitors are efficient to
decrease glucose uptake in vivo in muscle cells but not in vitro
as previously reported (Roy et al., 1998). In addition, apelin
also increased Akt phosphorylation in muscle manner both ex
vivo (Dray et al., 2008) and in vitro (Yue et al., 2010). Interest-
ingly, apelin is still able to stimulate glucose uptake in muscle
of obese and insulin-resistant mice. This leads to an overall bet-
ter insulin sensitivity (Dray et al., 2008). The role of apelin in
glucose homeostasis was confirmed by the phenotype of apelin
null (apelin−/−) mice exhibiting hyperinsulinemia and insulin
resistance (Yue et al., 2010). The loss of insulin sensitivity in
apelin−/− mice was exacerbated by a high fat/ high sucrose diet
(Yue et al., 2010).
Even though apelin-induced glucose transport has not yet
been reported in isolated mouse adipocytes, apelin stimulates
glucose transport in an AMPK-dependent way in human adi-
pose tissue explants (Attane et al., 2011). This has also been
observed in 3T3-L1 adipocytes through a mechanism dependent
on PI3K/Akt activation but the role of AMPK was not studied
(Zhu et al., 2011). In addition, in insulin-resistant 3T3-L1 cells
(due to TNFα treatment), apelin increases the insulin-stimulated
glucose transport (Zhu et al., 2011). Skeletal muscle and adipose
tissue are not the only tissues where apelin stimulates the entry
of glucose. In vivo, apelin has been shown to increase myocardial
glucose uptake and Glut4 membrane translocation in C57BL/6J
mice (Xu et al., 2012). Apelin also increases glucose transport
in vitro, in H9C2 cardiomyoblasts (Xu et al., 2012). A role of
apelin has also been shown in intestinal glucose absorption.
Ingested glucose can rapidly induce the secretion of apelin in
the intestinal lumen in mice (Dray et al., 2013). This study also
shows that, when apelin is administered orally, the amount of
glucose transporters SGLT1 is decreased in enterocytes, whereas
that of Glut2 is increased due to AMPK activation. This results
in an increased intestinal absorption of glucose. These data sug-
gest that glucose arrival in the intestine causes its own absorp-
tion by inducing the paracrine secretion of apelin. A transient
increase in blood glucose levels in the portal vein could induce
rapid secretion of insulin (Fukaya et al., 2007), and an improved
insulin sensitivity (Burcelin et al., 2000; Delaere et al., 2010).
Thus, apelin could also regulate glucose metabolism, by promot-
ing glucose absorption by the enterocytes and then by increas-
ing portal blood glucose and insulin secretion. This could be in
agreement with the fact that apelin was shown to increase GLP-1
secretion (Wattez et al., 2013).
Although all studies did not report a significant decrease
in fasting blood glucose in obese and insulin resistant mice in
response to apelin, decreased insulinemia has frequently been
observed. This may be the result of improved insulin sensitivity
or a direct effect of exogenous apelin on the pancreas. Accord-
ingly, apelin was shown to decrease insulin secretion stimulated
by different glucose concentrations (Guo et al., 2009; Ringstrom
et al., 2010). Thus, by activating AMPK and bypassing insulin sig-
naling, apelin exerts direct anti-diabetic effects, which could have
an important impact in insulin resistant conditions.
Apelin and Lipid Metabolism
Few publications describe acute effects of apelin on lipid
metabolism. In both isolated adipocytes and differentiated
3T3-L1 adipocytes, apelin was shown to inhibit isoproterenol
(β-adrenergic agonist) -induced lipolysis through a pathway
involving Gq, Gi, and AMPK (Yue et al., 2011). These results
were confirmed by Than et al. (2012), who showed that apelin
decreases the release of FFA by 3T3-L1 adipocytes through
AMPK activation and by increasing the amount of perilipin sur-
rounding the lipid vacuoles, giving them a greater stability and a
resistance to lipases (Than et al., 2012). However, in human adi-
pose tissue explants or human isolated adipocytes, apelin had no
effect on basal or isoproterenol-stimulated lipolysis (Attane et al.,
2011). Effects on adipose tissue and lipolysis were also found
in vivo after a chronic apelin treatment in standard or high-fat
diet (HFD) fed mice. Indeed, Higuchi et al. showed that daily ip
apelin injections during 2 weeks decrease the triglycerides con-
tent in adipose tissue and the weight of different fat depots in
standardmice and in HFD fedmice (Higuchi et al., 2007). Similar
results were obtained in transgenic mice over-expressing apelin
(Tg-apelin mice) fed a HFD (Yamamoto et al., 2011).
Chronic apelin treatment, in obese and insulin resistant
mice, was also shown to increase fatty acid oxidation in mus-
cles through AMPK activation (Attane et al., 2012). More
recently, chronic apelin treatment has also been shown to pre-
vent reduction of fatty acid and glucose oxidation in a model
of obesity-related decline of cardiac function (Alfarano et al.,
2015). In addition to stimulate the utilization of lipids, apelin
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FIGURE 1 | Metabolic effects of apelin and its main signaling
targets. Apelin, the ligand of the G protein coupled receptor APJ, can
stimulate several metabolic functions (green arrows/boxes) and inhibit
(orange arrows/boxes) lipolysis as well as insulin secretion through
different signaling pathways: PDE3B, phosphodiesterase 3B; AMPK,
AMP-activated protein kinase; PGC1-α, peroxisome proliferator-activated
receptor γ co-activator 1α; eNOS, endothelial NO synthase; PI3K,
phosphatidylinositol 3-kinase and Akt.
treatment increases mitochondrial biogenesis in skeletal muscle
(Attane et al., 2012) and cardiomyocytes (Alfarano et al., 2015)
by a mechanism involving increased expression of peroxi-
some proliferator-activated receptor γ co-activator 1α (PGC1α).
Increasedmitochondrial DNA content in skeletal muscle was also
found in Tg-apelin mice (Yamamoto et al., 2011) in agreement
with the effect of apelin on mitochondrial biogenesis. Interest-
ingly, the resistance to obesity of Tg-apelin mice was correlated
with an increase in vessel formation in skeletal muscle. The
importance of vessels integrity in both blood and lymph vascu-
lature was recently confirmed in apelin−/− mice (Sawane et al.,
2013). Indeed, weight gain observed in apelin−/− mice could
be related to increased vascular permeability that in turn would
induce greater fatty acids uptake in adipose tissue (Sawane et al.,
2013). Thus, apelin might also prevent development of obesity
through the maintenance of vascular integrity.
Energy expenditure in response to apelin treatment has also
been studied via thermogenesis. Higuchi et al. reported that rectal
temperature and O2 consumption were higher in apelin-treated
chow-fed mice probably mediated by the increased expression of
mitochondrial uncoupling protein 1 (UCP1) observed in brown
adipose tissue (Higuchi et al., 2007). O2 consumption and body
temperature were also increased in HFD fed Tg-apelin mice
(Yamamoto et al., 2011) but not in obese and insulin resistant
mice in response to chronic apelin treatment (Attane et al., 2012).
However, food intake was not altered in both models.
All together, these studies clearly show that apelin, by itself,
exerts metabolic functions such as glucose uptake but also
improves insulin sensitivity since, for example, at the end of
chronic apelin treatment, insulin-induced glucose transport was
increased in skeletal muscles and there is an overall better insulin
and glucose tolerance (Attane et al., 2012). Therefore apelin could
be proposed as an interesting therapeutic target in the treatment
of type 2 diabetes.
Changes in Apelin Concentrations Related
to Human Metabolic Diseases
Numerous studies have reported increased plasma apelin
concentrations in obese and/or diabetic subjects (for review see
Castan-Laurell et al., 2011). Apelin-17 and [pyr-1]-apelin-13 may
represent the predominant forms in plasma (De Mota et al.,
2004; Azizi et al., 2008). During the last years, additional infor-
mation was provided by assays performed especially in diabetic
patients and in patients involved in weight loss intervention stud-
ies. Interestingly, plasma apelin has been shown to be a novel
biomarker for predicting diabetes in Han Chinese subjects (Ma
et al., 2014). Plasma apelin concentrations were higher in women
than in men but they were associated with a risk of diabetes
only in men (Ma et al., 2014). Recent data have also shown that
apelin concentrations were significantly higher in type 1 diabetic
patients than in control subjects and even higher than in type
2 diabetic patients (Habchi et al., 2014), in line with the previ-
ous study of Alexiadou et al. focused on type 1 diabetic subjects
(Alexiadou et al., 2012). All together these studies pointed out
the role of systemic apelin in metabolic diseases. What is the
meaning of elevated apelinemia? Is obesity a main determinant of
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elevated plasma apelin concentration? Different elements could
be provided. Habchi et al. demonstrated that serum apelin levels
were negatively correlated with glycosylated hemoglobin in type
2 diabetic patients, suggesting that circulating apelin is associ-
ated with better glycaemic control (Habchi et al., 2014). Increased
concentrations of apelin in type 1 diabetes could be an attempt
to compensate for the lack of insulin and to overcome insulin
resistance. However patients were also treated with insulin, which
could as well explain this rise, since insulin is one of the most
important regulator of apelin expression and secretion (Boucher
et al., 2005). Moreover, type 1 diabetic patients are not obese,
suggesting that obesity is probably not the main determinant of
increased apelin levels. In line with this point, an absence of cor-
relation between plasma apelin concentrations and BMI has often
been described (Castan-Laurell et al., 2011). The recent study
of Krist et al. also gives further insights. They aimed to investi-
gate whether changes in circulating apelin, in a context of weight
loss, are primarily due to a reduced body fat mass or reflect the
improved insulin sensitivity. First, all the different weight loss
intervention studies (hypocaloric diet, bariatric surgery or exer-
cise program) reduced the elevated serum apelin concentration
determined in different cohorts of obese and diabetic patients
as previously reported (Heinonen et al., 2009; Castan-Laurell
et al., 2011). Secondly, significant BMI-independent correlations
between reduced apelin levels and improved insulin sensitivity
were found (Krist et al., 2013). Thus, it could be hypothesized that
the increased plasma apelin observed in type 2 diabetic patients,
is, as in type 1 diabetes, a compensatory mechanism devoted to
directly decrease insulin resistance since apelin exerts different
metabolic actions itself. When insulin resistance is decreased, this
may lead to decreased apelin levels. It has thus been proposed
that lower apelin serum concentrations in healthy lean individu-
als may be a consequence rather than a cause of normal insulin
sensitivity (Krist et al., 2013).
Conclusion
The metabolic effects of apelin (Figure 1) described in differ-
ent mouse models (diet-induced obesity, transgenic models)
have underlined the beneficial roles of apelin on both energy
metabolism and insulin sensitivity. Still, there remainmany ques-
tions and many tools need to be developed. Long term apelin
treatment studies, in both healthy and pathological conditions,
need a more integrative view including cardiac, vascular and cen-
tral effects. The methods used for apelin quantification include
enzyme immunoassays and radioimmunoassays but give a wide
range of basal values depending on the studies. More reliable
assays, easy to use, are necessary. It will also be important to
know whether the elevated serum apelin concentrations corre-
spond to active apelin and what are the predominant forms of
apelin in metabolic diseases and their variations. Finally, selec-
tive agonists and antagonists for APJ started to be developed
but they need to be tested on metabolic tissues and their sig-
naling more largely described. All these points are important
in order to validate the promising anti-diabetic properties of
apelin.
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